ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

OPY Oppenheimer Holdings Inc

40.80
1.84 (4.72%)
26 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Oppenheimer Holdings Inc NYSE:OPY NYSE Common Stock
  Price Change % Change Share Price High Price Low Price Open Price Shares Traded Last Trade
  1.84 4.72% 40.80 41.245 39.24 39.24 33,889 22:30:00

Oppenheimer Hires Suraj Kalia As Managing Director And Senior Analyst In Medical Technology And Devices

07/10/2019 6:30pm

PR Newswire (US)


Oppenheimer (NYSE:OPY)
Historical Stock Chart


From Apr 2019 to Apr 2024

Click Here for more Oppenheimer Charts.

NEW YORK, Oct. 7, 2019 /PRNewswire/ -- Oppenheimer & Co. Inc. ("Oppenheimer") – a leading investment bank, wealth manager, and a subsidiary of Oppenheimer Holdings (NYSE: OPY) – today announced that Suraj Kalia has joined the Firm as Managing Director and Senior Medical Technology Analyst.  

Kalia covers Medical Technology and Devices within Oppenheimer's Healthcare Research franchise. He is responsible for providing clients with expert insight on the growing medical technology and devices sector. He brings more than 15 years of sell-side research experience to this role.

"Suraj's proven track record of delivering precise, cutting-edge analysis of the medical technology sector supports our mission of providing our clients with insights from the brightest minds in the industry," said John Parks, Managing Director & Director of Equity Research. "He has appeared on several esteemed rankings and lists by prominent publications, and his research is well-recognized. Given Oppenheimer's core focus on this industry, Suraj is the perfect addition to our team of experts."

Prior to joining Oppenheimer, Kalia was a Managing Director and Senior MedTech Analyst at Northland Securities, where he was ranked as the top Healthcare Equipment and Supplies Analyst by Thomson Reuters in 2018. His acclaimed market and company-specific research focused on Obstructive Sleep Apnea, Refractory Hypertension, Obesity, Epilepsy and Refractory Depression. Kalia was also a Managing Director and Senior Medical Device Analyst at Rodman & Renshaw, and a Senior Medical Device Analyst at Piper Jaffray & Co.

Kalia holds a bachelor's degree in technology, chemical engineering from the Indian Institute of Technology Bombay and a master's degree in chemical engineering from Stevens Institute of Technology. He also holds a Master of Business Administration from the University of St. Thomas and the CFA certification. He is based in New York City.

Oppenheimer & Co. Inc
Oppenheimer & Co. Inc. (Oppenheimer), a principal subsidiary of Oppenheimer Holdings Inc. (OPY on the New York Stock Exchange), and its affiliates provide a full range of wealth management, securities brokerage and investment banking services to high-net-worth individuals, families, corporate executives, local governments, businesses and institutions.

Cision View original content:http://www.prnewswire.com/news-releases/oppenheimer-hires-suraj-kalia-as-managing-director-and-senior-analyst-in-medical-technology-and-devices-300933144.html

SOURCE Oppenheimer & Co. Inc.

Copyright 2019 PR Newswire

1 Year Oppenheimer Chart

1 Year Oppenheimer Chart

1 Month Oppenheimer Chart

1 Month Oppenheimer Chart

Your Recent History

Delayed Upgrade Clock